Nicola J Nasser1, Gil'ad N Cohen2, Lawrence T Dauer2, Michael J Zelefsky3. 1. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: zelefskm@mskcc.org.
Abstract
PURPOSE: Prostate low-dose-rate (LDR) brachytherapy involves implantation of radioactive seeds permanently into the prostate gland. During receptive anal intercourse, the penis of the partner may come in close proximity to the implanted prostate gland. We estimate the potential intrarectal dose rates and suggest guidance on radiation precautions. METHODS AND MATERIALS: One hundred two patients were included in the study. After implantation, with patients under anesthesia in the dorsal lithotomy position, a new set of ultrasound (US) images and a CT scan were obtained. The images were fused, radioactive seeds and US probe locations were determined on the CT, and prostate, bladder, and rectal contours were drawn on the US. Dose rates (cGy/h) were calculated for the portion of the US probe spanning the prostate for several dose-volume histogram parameters. RESULTS: Twenty patients were treated with (125)I and 82 patients with (103)Pd. Average dose rates at Day 0 to the portion of the US probe spanning the prostate were 2.1 ± 1.3 cGy/h and 2.5 ± 0.8 cGy/h for patients treated with (125)I and (103)Pd, respectively. After 60 days, average calculated probe dose drops to 1.0 ± 0.6 cGy/h and 0.2 ± 0.1 cGy/h for (125)I and (103)Pd, respectively. CONCLUSIONS: During the immediate weeks after prostate seed implant, the estimated intrarectal dose rates are higher in (103)Pd compared to (125)I. As (103)Pd decays faster than (125)I, 2 months after the implant, radiation exposure from (103)Pd becomes lower than (125)I. Receptive anal intercourse time should be kept as low as possible during 2 and 6 months after low-dose-rate brachytherapy of the prostate with (103)Pd and (125)I, respectively.
PURPOSE: Prostate low-dose-rate (LDR) brachytherapy involves implantation of radioactive seeds permanently into the prostate gland. During receptive anal intercourse, the penis of the partner may come in close proximity to the implanted prostate gland. We estimate the potential intrarectal dose rates and suggest guidance on radiation precautions. METHODS AND MATERIALS: One hundred two patients were included in the study. After implantation, with patients under anesthesia in the dorsal lithotomy position, a new set of ultrasound (US) images and a CT scan were obtained. The images were fused, radioactive seeds and US probe locations were determined on the CT, and prostate, bladder, and rectal contours were drawn on the US. Dose rates (cGy/h) were calculated for the portion of the US probe spanning the prostate for several dose-volume histogram parameters. RESULTS: Twenty patients were treated with (125)I and 82 patients with (103)Pd. Average dose rates at Day 0 to the portion of the US probe spanning the prostate were 2.1 ± 1.3 cGy/h and 2.5 ± 0.8 cGy/h for patients treated with (125)I and (103)Pd, respectively. After 60 days, average calculated probe dose drops to 1.0 ± 0.6 cGy/h and 0.2 ± 0.1 cGy/h for (125)I and (103)Pd, respectively. CONCLUSIONS: During the immediate weeks after prostate seed implant, the estimated intrarectal dose rates are higher in (103)Pd compared to (125)I. As (103)Pd decays faster than (125)I, 2 months after the implant, radiation exposure from (103)Pd becomes lower than (125)I. Receptive anal intercourse time should be kept as low as possible during 2 and 6 months after low-dose-rate brachytherapy of the prostate with (103)Pd and (125)I, respectively.
Authors: Lawrence T Dauer; Michael J Zelefsky; Christopher Horan; Yoshiya Yamada; Jean St Germain Journal: Brachytherapy Date: 2004 Impact factor: 2.362
Authors: Brian J Davis; Eric M Horwitz; W Robert Lee; Juanita M Crook; Richard G Stock; Gregory S Merrick; Wayne M Butler; Peter D Grimm; Nelson N Stone; Louis Potters; Anthony L Zietman; Michael J Zelefsky Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Daniel E Spratt; Zachary S Zumsteg; Pirus Ghadjar; Marisa A Kollmeier; Xin Pei; Gilad Cohen; William Polkinghorn; Yoshiya Yamada; Michael J Zelefsky Journal: BJU Int Date: 2014-01-22 Impact factor: 5.588
Authors: Vinayak Muralidhar; Brandon A Mahal; David R Ziehr; Yu-Wei Chen; Michelle D Nezolosky; Vidya B Viswanathan; Clair J Beard; Phillip M Devlin; Neil E Martin; Peter F Orio; Paul L Nguyen Journal: Brachytherapy Date: 2015-04-14 Impact factor: 2.362
Authors: Lawrence T Dauer; Marisa A Kollmeier; Matthew J Williamson; Jean St Germain; Joaquin Altamirano; Yoshiya Yamada; Michael J Zelefsky Journal: Brachytherapy Date: 2009-10-22 Impact factor: 2.362
Authors: Lara Hathout; Michael R Folkert; Marisa A Kollmeier; Yoshiya Yamada; Gil'ad N Cohen; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-01 Impact factor: 7.038
Authors: Benjamin D Capistrant; Lindsey Lesher; Nidhi Kohli; Enyinnaya N Merengwa; Badrinath Konety; Darryl Mitteldorf; William G West; B R Simon Rosser Journal: Oncol Nurs Forum Date: 2018-07-02 Impact factor: 2.172
Authors: Shearwood McClelland; Daniel G Petereit; Ross Zeitlin; Cristiane Takita; Gita Suneja; Robert C Miller; Curtiland Deville; Malika L Siker Journal: Adv Radiat Oncol Date: 2020-08-06